Arena gets 10/22 PDUFA date for lorcaserin

Arena Pharmaceuticals should know by October 22 if its closely-watched obesity drug--lorcaserin--will win approval by the FDA. The drug is widely viewed as a likely blockbuster if it breaks into the huge market for weight-loss drugs. "With an October PDUFA date for the lorcaserin NDA, we are another step closer to our goal of improving the treatment of obesity. We believe that lorcaserin, if approved, will be well positioned as first-line therapy to help patients achieve sustainable weight loss in a well-tolerated manner," says CEO Jack Lief. A total of 8,576 patients have been enrolled in 18 clinical trials for the therapy. Arena release

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.